Dishman Pharmaceuticals and Chemicals, city-based contract research and manufacturing services (CRAMS) player is reportedly planning to introduce 60 generic active pharmaceutical ingredients (APIs) by the end of 2013-14 financial year. Of this, at least 30 APIs will be launched during FY13, while the remaining will be launched during FY14.
The company has already filed 20 drug master files (DMFs), and another 20 DMFs are in the pipeline. The company’s product portfolio includes antiseptic, anaesthetic, laxative, anti-diabetic, anti-fungal, diuretic, analgesic, anti-ulcer segments.
Dishman Pharmaceuticals and Chemicals is engaged in manufacturing of Bulk API, Intermediates, Specialties and Quats. The company has started production of a range of phase transfer catalysts and quaternary ammonium and phosphonium compounds in 1989.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: